Drug Quality Sampling and Testing Programs

Why It Matters

Ensuring drug quality protects U.S. patients from ineffective or unsafe medicines and reinforces confidence in the pharmaceutical supply chain.

Key Takeaways

• Risk‑based testing increased failure detections since 2018
• Most FY 25 samples passed identity, assay, and impurity tests
• Atorvastatin dissolution failure highlights import surveillance value
• FDA shares findings with clinicians and manufacturers promptly
• Continuous monitoring drives compliance across domestic and foreign producers

Pulse Analysis

The FDA’s drug quality surveillance program has evolved into a sophisticated, risk‑based system that leverages post‑market data analytics to pinpoint vulnerable products before they reach patients. By focusing resources on imports and high‑risk categories, the agency can conduct targeted assays—identity, potency, impurity, dissolution, and sterility—aligned with United States Pharmacopeia standards. This strategic shift, implemented in 2018, has already yielded a higher detection rate of quality failures, reinforcing the United States’ reputation for stringent pharmaceutical oversight.

In FY 25, the CDER testing roster encompassed a broad spectrum of therapeutic classes, from antihistamines and antidiabetics to cardiovascular agents and central nervous system drugs. The overwhelming pass rate—exceeding 99 percent—demonstrates that most manufacturers, both domestic and overseas, adhere to Good Manufacturing Practices. However, the dissolution failure of an atorvastatin batch underscores the importance of import surveillance, as sub‑optimal dissolution can compromise drug absorption and therapeutic efficacy. Such findings trigger immediate alerts to healthcare providers and compel manufacturers to remediate production processes.

For the industry, these results signal a clear expectation: compliance is non‑negotiable, and data‑driven oversight will only intensify. Companies that integrate robust quality control, real‑time analytics, and transparent reporting into their supply chains will mitigate regulatory risk and maintain market access. Meanwhile, clinicians and patients benefit from heightened assurance that the medications dispensed in U.S. pharmacies meet rigorous safety and efficacy benchmarks.